Core Insights - Nuvation Bio Inc. (NYSE:NUVB) is recognized as a promising low-cost stock under $5, particularly following the FDA approval and commercial launch of Ibtrozi (Taletrectinib) for ROS1-positive non-small cell lung cancer, with a significant uptake of 432 new patient starts by year-end, outpacing competitors by sixfold [1][2] Financial Performance - The company reported $41.9 million in revenue for Q4, supported by a robust cash position of $529.2 million, bolstered by international partnerships with Eisai and Nippon Kayaku [1] Drug Development and Market Strategy - Nuvation Bio is focusing on increasing revenue stability as first-line patient penetration improves through 2026, emphasizing Ibtrozi's differentiated clinical profile, including a 50-month median duration of response in TKI-naive patients and a favorable safety profile [2] - The company has initiated the TRUST-4 Phase 3 study targeting early-stage patients for Ibtrozi, and is advancing its second lead program, safusidenib, for IDH1-mutant glioma, with the Phase 3 SIGMA trial recently launched for high-grade patients [3][4]